Takeaway
Exploratory study identifies baseline risk factors for motor and cognitive symptom progression in patients with Parkinson’s disease (PD).
Why this matters
Identification of different PD-specific biomarkers and disease trajectories can help in enhancing effectivity of neuroprotective therapies.